AT 301
Alternative Names: AT-301; Inactivated H5N1 influenza virion vaccine - Medigen Biotechnology CorporationLatest Information Update: 06 Apr 2016
Price :
$50 *
At a glance
- Originator Medigen Biotechnology Corporation
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Influenza A virus H5N1 subtype
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 12 Nov 2013 AT 301 is available for licensing (www.medigen.com.tw/eng)
- 05 Sep 2012 Phase-I clinical trials in Influenza-A virus H5N1 subtype (Prevention, in volunteers) in Taiwan (IM)
- 01 Aug 2012 Preclinical trials in Influenza-A virus H5N1 subtype (Prevention) in Taiwan (IM)